Migraine Primary Care Conference July 29, 2010 Samuel Ash, MD Resident, Internal Medicine University of Washington samash@uw.edu Outline Cases Epidemiology Costs Pathophysiology Diagnosis Treatment • Abortive • Preventative Special considerations Summary Cases Case Number 1: 32 year old woman with no other significant medical history who states that she has frequent severe headaches and has previously been diagnosed with migraine. Cases Case Number 2: 43 year old woman with self-reported history of: • • • • • Migraine without aura Seizure disorder Depression Anxiety PMDD Chart history of: • Axis II, cluster B disorder • Benzodiazepine and opiate dependence/abuse Epidemiology 1 year prevalence: • overall: 11.7% women: 17.1% men: 5.6% • additional 4.5% have "probable migraine“ Lifetime prevalence: • Women: 25% • Men: 8% Image from yourhealth.net.au Epidemiology Epidemiology Chronic migraine: • 1-year period prevalence 1-2% Migraine among neurologists • 50% prevalence Migraine among headache specialists • 75% prevalence Epidemiology http://www.aiws.info/ Famous migraineurs (suspected or known) • • • • • • • • • • • • • Lewis Carroll Elvis Presley Joan of Arc Elizabeth Taylor Julius Caesar Napoleon Bonaparte Thomas Jefferson Ulysses Grant Frederich Nietzsche Sigmund Freud Claude Monet Alexander Graham Bell Terrell Davis Cost to Society Direct Costs: • Total cost of annual medical care: Family with migraineur: $7007 per year Family without migraineur: $4435 per year • National Burden: $11 billion $4.6 $5.2 $0.5 $0.7 billion billion billion billion was in prescription drugs in outpatient costs in ER in inpatient costs Cost to Society Indirect Costs: • Estimated to be approximately $13.3 billion • Due to missed work days and impaired work performance • Does not include: unemployment or underemployment burden experienced between attacks lost home-worker time due for chores lost time because of caring for family members with migraine. Pathophysiology ? Genetics Familial hemiplegic migraine • Three different abnormal genes • Mutations relate to ion channel function and neuronal hyperexcitability Genetics 1p13.3 Glutathione S-Transferase (GST) MO 1 p36 MTHF-R MA 4 q24 ? MA & MO 4q31.2 Endothelin type A (ETA-231 A/G) Not specified 6p21.3 Tumor necrosis factor α (TNFα) Not specified 6p21.3 HLA-DRB1 MO 6q25.1 Estrogen receptor 1 (ESR1) MA & MO 6q25.1 Estrogen receptor 1 (ESR1) Not specified Females only 9q34 Dopamine β-hydroxylase (DBH) Not specified 11 q24 ? MA 11 p15 DRD4 MO 11q22-23 Progesterone receptor (PGR) MA & MO 11q23 DRD2 Allele 1 TG dinucleotide noncoding MO 11q23 Dopamine D2 (DRD2) NcoI MA 14 q21-22 ? MO 17q11.1-q12 Human serotonin transporter (SLC6A4) MA & MO 17q23 Angiotensin converting enzyme (ACE) MO 19p13.3/2 Insulin receptor INSR Not specified 22q11.2 Catechol-Omethyltransferase (COMT) not specified X q24-28 ? MO 4 q21 Pathophysiology Syndromic approach with migraine as “final common pathway” Maladaptive activation of trigeminal cervical pain apparatus • Early warning system to protect the brain and cervical cord from injury Pathophysiology Aura • cortical spreading depression • initially decreased and then increased blood flow • may be related to initiation of migraine Image courtesy of http://migraine.co.nz/ Pathophysiology Micro-emboli • Increased prevalence of PFO in patients with migraine with aura • Uncontrolled of PFO closure trials promising • Controlled studies thus far not as promising Types of Migraine Migraine without aura (common migraine) Migraine with aura (classic migraine) • • • • • • Typical aura with migraine headache Typical aura with non-migraine headache Typical aura without headache Familial hemiplegic migraine Sporadic hemiplegic migraine Basilar-type migraine Diagnosis International Classification of Headache Disorders (ICHD) Very detailed set of criteria available at: http://www.ihsclassification.org/en Diagnosis Alternative (ie shorter) history: • POUND Pulsatile quality of headache One day duration (usually 4-72 hours) Unilateral location Nausea or vomiting Disabling intensity • 3/5 criteria = likely migraine • 4/5 criteria = very likely to be migraine Diagnosis Prodrome vs. Aura • Prodrome Euphoria, depression, fatigue, hypomania, food cravings, dizziness, cognitive slowing, or asthenia Occurs in 60-70% of migraine patients • Aura Visual changes, loss of vision, hallucinations, numbness, tingling, weakness, or confusion Occurs in 15-20% of migraine patients Diagnosis Consider headache diary to better determine triggers, etc. http://www.relieve-migraine-headache.com/diary-headache-migraine.html Developmental History Childhood periodic syndromes that are commonly precursors of migraine • Cyclical vomiting • Abdominal migraine • Benign paroxysmal vertigo of childhood Alarm Features Alarm Features Based on History Changes in headache pattern/freq/intensity Daily headache Blurred vision Dizziness/syncope/discoordination/focal neuro deficits Sudden/explosive onset Pain worse with coughing Change in personality Headache that wakes you up from sleep Onset after 50 years of age Alarm Features Based on Physical • • • • • • • • • Vitals: fever or hypertension (diastolic >120) Mental status change Meningeal signs Diminished pulse or tenderness of temporal artery Focal neurologic deficits: including visual acuity Papilledema Intraocular pressure Necrotic or tender scalp lesions Other signs of infection Labs ESR • Indicated for new onset headache if age>50 • Screens for temporal arteritis and other vasculitides • Obtain even if symptoms consistent with migraine • Headache is predominant feature in 6580% of patients with temporal arteritis Neuro-Imaging Neuro-Imaging Consider if: • Atypical migraine features • Substantial change in headache pattern • Signs or symptoms of neurologic abnormalities EEG Consider only if associated symptoms suggest a seizure disorder. No useful headache subtype groups are defined by EEG EEG is not able to identify patients with structural cause of headaches Treatment “My migraine only gets better with that ‘d’ drug. You know, d…d…dilaudid…” “My dilaudid only works IV and only if I get at least 8mg at once.” “I have to get benadryl with it or I get itchy – I need 50mg… It has to be IV.” “I’m sooo nauseated too. I’m allergic to all the anti-nausea medications except IV phenergan.” - Patient from my last night in the UWMC ED Treatment Brust’s Rule: if we have a lot of treatments for a disease… none must work very well… Images from migraine support blogs Treatment: Non-Pharmacologic Treatment: Non-Pharmacologic Diet • Some benefit to elimination diets • 20% of patients report dietary triggers • Common triggers: Caffeine withdrawal Packaged meats MSG Dairy Fatty foods Aged cheese Red wine Beer Champagne Chocolate Treatment: Non-Pharmacologic Alcohol • “If you must drink, no more than two normal size drinks” • “Suggested drinks: Riesling Seagram’s VO Cutty Sark Vodka” - As per Diamond S and Dalessio DJ. The practicing physician’s approach to headache. New York: Williams and Wilkings. 1982. Treatment: Non-Pharmacologic Behavioral • Shown to be effective 30-50% reduction of migraine frequency Modalities • • • • Relaxation training Thermal biofeedback with relaxation training Electromyogram biofeedback Cognitive behavioral therapy • No data to guide selection of modality… Treatment: Abortive Tenets: • Educate migraine sufferers • Use migraine specific agents in severe disease • Non-oral route for patients with significant nausea and vomiting • Be aware of medication overuse and rebound Treatment: Abortive When to treat? • EARLY • Within 2 hours • Treatment during prodrome or aura is even more effective Image courtesy of denverpost.com Treatment: Mild to Moderate NSAIDS • Ibuprofen • Naproxen • Diclofenac • Tolfenamic acid • Indomethacin suppository Aspirin Tylenol Combinations Treatment: Severe If severe symptoms present then don’t bother with OTC preparations • Improved outcomes with migraine specific therapy Consider route of administration Consider contraindications/PMH Treatment: Triptans First line • More effective • Less nausea Contraindications • CAD • Cost Routes • Oral • Intranasal • Subcutaneous Image courtesy of headaches.about.com Treatment: Triptans Mechanism of Action • Selective serotonin agonist • 5HT1B/1D Pharmacokinetics/dynamics • Both long and short acting available • Long acting more effective during aura but take longer to act • Short acting have more side effects Treatment: Triptans Options • Sumatriptan (subq/nasal/oral) • Almotriptan (oral) • Eletriptan (oral) • Frovatriptan (oral) • Naratriptan (oral) • Rizatriptan (oral/ODT) • Zolmitriptan (oral) Treatment: Triptans Which one to choose… • No class effect • Recurrent headache may indicate need for repeat dose, not new triptan • Pharmacokinetics/dynamics • Side effect profile Treatment: Triptans Which one to choose… • Specific concerns Teratogenicity Menstrual migraine Subq • not effective during prodrome/aura • More contraindications Treatment: Dihydroergotamine Mechanism of Action • Non-selective serotonin agonist Routes • • • • Nasal Subq IM IV Contraindications • Pregnancy (category X) • Cannot be used with a triptan • IV contraindicated in CAD Treatment: Adjuncts Anti-emetics • Metoclopromide both as adjunct and mono-therapy • Ondansetron IV/oral/ODT Caffeine • Rebound Steroids • Dexamethasone • Prednisone Treatment: Rescue Opiates • Should be used only a few times per year Up to ½ of patients with recurrent headache do not adhere to drug treatment regimen Treatment: Prevention Treatment: Prevention Definitely consider: • Disabling headaches > 2x per month • Poor relief from abortive therapy • Uncommon migraine Basilar Hemiplegic Might consider: • Contraindication to acute therapy • Failure of acute therapy • Preference for preventative therapy Treatment: Prevention Rules to live by: • Headache diary • Patience • No right agent • Consider: Side effects Other benefits Treatment: Prevention Antihypertensives • All agents effective • Best evidence for beta blockers • Limited evidence for CCB • ACE and ARB also effective • No evidence for diuretics Treatment: Prevention Antidepressants • Depression or other psychiatric disorder often co-morbid condition • Lack of evidence for SSRIs • Tricyclics and mirtazepine shown to have some benefit Treatment: Prevention Anticonvulsants • Valproate (FDA approved) At least as effective as b-blocker May be better tolerated • Topiramate (FDA approved) Requires slightly higher doses Weight loss benefit • Gabapentin Not FDA approved but appears effective Treatment: Prevention Other agents • Botulinum toxin injections: not recommended • Coenzyme Q10: small studies • Magnesium: mixed results • Butterbur (herbal): minimal evidence • Feverfew (herbal): results Special Consideration: Rebound and Overuse Can occur with almost any headache medication To avoid: • Limit acute medications to no more than 10 days per month • Preventative therapies as mainstay of treatment • Use headache diary Special Consideration: Hospitalization Status migranosis • Prolonged (>72h), intractable migraine • Associated nausea and vomiting Overuse headache • Inpatient weaning Special Consideration: Menstrual Migraine Estrogen effects Two types • Pure menstrual migraine • Menstrually related migraine Treatment • • • • • Usual abortive therapy Estrogen-progestin OCP in extended cycle Menstrually targeted supplemental estrogen Long acting triptan prophylaxis Some evidence for SERMs Special Consideration: Migraine and Stroke WHO • Avoid estrogen containing OCPs: Migraine + over age of 35 Migraine with aura ACOG • Avoid estrogen containing OCPs: Migraine + over age of 35 Migraine + focal neurologic signs Migraine + smoking Special Consideration: Other Migraine Disorders Retinal migraine Complications of migraine • Chronic migraine • Status migrainosus • Persistent aura without infarction • Migrainous infarction • Migraine-triggered seizure Special Consideration: Other Migraine Disorders Probable migraine • Probable migraine without aura • Probable migraine with aura • Probable chronic migraine Summary Migraine is exceedingly common • 1 in 4 women, nearly 1 in 10 men Unclear pathophysiology Diagnosis based primarily on history • POUND Treatment • Abortive: focus on migraine specific therapies • Preventative: focus on patience Special cases Resources and Further Reading Bartleson JD and Cutrer M. Migraine Update: Diagnosis and Treatment. Minn Med. May 2010. In the Clinic: Migraine. Annals of Int Med. 2007;9:1-16. Dr. Natalia Murinova • UWMC Headache Clinic References Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci. 2008;28(46):11768-77. Charles A. Advances in the basic and clinical science of migraine. Ann Neurol. 2009;65(5):491-8. Cutrer FM. Pathophysiology of Migraine. Semin Neurol 2010; 30(2): 120-130. Evans RW, Lipton RB, Silberstein SD. The prevalence of migraine in neurologists. Neurology 2003;61:1271-2. Evans RW. Migraine: A question and answer review. Med Clin N Am 2009;93:245-62. General Household Survey, Office for National Statistics. Fourth National Morbidity Study from General Practice 1991/92, Office for National Statistics. http://www.statistics.gov.uk/ Hawkins K, Rupnow M, Wang S. Direct cost burden of migraine among members of US employers. Value Health 2006;9:A85. References Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States. Value Health 2009;12:55-64. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813–8. IHS – International Headache Society; http://www.ihsclassification.org/en/ Lipton RB, Bigal, ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:348-9. Michel P, Dartigues JF, Henry P, et al. Validity of the IDHS criteria for migraine. Neuroepidemiology. 1993;12:51-7. Silberstein S, Loder E, Diamond S, et al. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention Study. Cephalagia 2007;27:220-34. UpToDate. Online 18.2.